Results 1 to 10 of about 378,238 (343)

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial

Lancet Oncology, The, 2023
BACKGROUND The approval of Bruton tyrosine kinase (BTK) inhibitors in patients with previously untreated chronic lymphocytic leukaemia (CLL) was based on trials which compared ibrutinib with alkylating agents in patients considered unfit for fludarabine,
P. Hillmen, A. Pitchford, A. Bloor, A. Broom, Moya Young, B. Kennedy, R. Walewska, M. Furtado, G. Preston, J. Neilson, N. Pemberton, Gamal Sidra, N. Morley, K. Cwynarski, A. Schuh, F. Forconi, N. Elmusharaf, S. Paneesha, C. Fox, D. Howard, A. Hockaday, Julia M. Brown, D. Cairns, Sharon M Jackson, N. Greatorex, N. Webster, J. Shingles, S. Dalal, P. Patten, D. Allsup, A. Rawstron, T. Munir   +31 more
exaly   +2 more sources

Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

New England Journal of Medicine, 2010
John H Stone, Peter A Merkel, Robert F Spiera   +2 more
exaly   +2 more sources

Cyclophosphamide [PDF]

BMJ, 1963
Cyclophosphamide, a recently-developed alkylating agent that may be administered orally, intramuscularly, and intravenously, was given to 135 patients with a wide variety of malignant diseases. Significant benefit was obtained in patients with lymphomas and leukemias as well as malignant melanoma, multiple myeloma, and carcinoma of the ovaries ...
J, SOLOMON, M J, ALEXANDER, J L, STEINFELD   +2 more
openaire   +4 more sources

Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.

New England Journal of Medicine, 2023
BACKGROUND In patients undergoing allogeneic hematopoietic stem-cell transplantation (HSCT), a calcineurin inhibitor plus methotrexate has been a standard prophylaxis against graft-versus-host disease (GVHD).
J. Bolaños-Meade, M. Hamadani, Juan Wu, M. A. Al Malki, M. Martens, L. Runaas, H. Elmariah, Andrew R. Rezvani, Mahasweta Gooptu, Karilyn T. Larkin, B. Shaffer, Najla El Jurdi, A. Loren, M. Solh, Aric Hall, A. Alousi, Omer H Jamy, M. Perales, Janny M. Yao, Kristy Applegate, Ami S. Bhatt, L. Kean, Y. Efebera, R. Reshef, W. Clark, N. Difronzo, E. Leifer, M. Horowitz, Richard J. Jones, S. Holtan   +29 more
semanticscholar   +1 more source

Cyclophosphamide versus Placebo in Scleroderma Lung Disease

New England Journal of Medicine, 2006
Donald P Tashkin, Robert Elashoff, Jonathan Goldin   +2 more
exaly   +2 more sources

Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial.

The Lancet Respiratory Medicine, 2022
BACKGROUND Rituximab is often used as rescue therapy in interstitial lung disease (ILD) associated with connective tissue disease (CTD), but has not been studied in clinical trials.
T. Maher, Veronica A Tudor, P. Saunders, M. Gibbons, S. Fletcher, C. Denton, R. Hoyles, H. Parfrey, E. Renzoni, M. Kokosi, A. Wells, D. Ashby, M. Szigeti, P. Molyneaux   +13 more
semanticscholar   +1 more source

Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial.

Journal of the American Society of Nephrology, 2021
BACKGROUND A cyclic corticosteroid-cyclophosphamide regimen is the first-line therapy for membranous nephropathy. Compared with this regimen, rituximab therapy might have a more favorable safety profile, but a head-to-head comparison is lacking ...
F. Scolari, Elisa Delbarba, D. Santoro, L. Gesualdo, A. Pani, N. Dallera, Laila-Yasmin Mani, M. Santostefano, S. Feriozzi, M. Quaglia, G. Boscutti, A. Ferrantelli, C. Marcantoni, P. Passerini, R. Magistroni, F. Alberici, G. Ghiggeri, C. Ponticelli, P. Ravani   +18 more
semanticscholar   +1 more source

TrkB agonist antibody ameliorates fertility deficits in aged and cyclophosphamide-induced premature ovarian failure model mice

Nature Communications, 2022
Premature ovarian failure (POF) is a leading cause of women’s infertility without effective treatment. Here we show that intravenous injection of Ab4B19, an agonistic antibody for the BDNF receptor TrkB, penetrates into ovarian follicles, activates TrkB ...
Xunsi Qin, Yue Zhao, Tianyi Zhang, C. Yin, J. Qiao, Wei Guo, Bai Lu   +6 more
semanticscholar   +1 more source

A sore red eye with systemic involvement [PDF]

, 2010
The study of happiness has long been a playground for philosophical speculation. By lack of empirical measures of happiness, it was not possible to check propositions about the matter.
Lightman, SL, Pusey, CD, Shalchi, Z, Taylor, SRJ   +3 more
core   +2 more sources

Potential Protective Effects of Antioxidants against Cyclophosphamide-Induced Nephrotoxicity

International Journal of Nephrology, 2022
Cyclophosphamide is an alkylating antineoplastic agent, and it is one of the most successful drugs with wide arrays of clinical activity. It has been in use for several types of cancer treatments and as an immunosuppressive agent for the management of ...
Muluken Altaye Ayza, Kaleab Alemayehu Zewdie, Elias Fitsum Yigzaw, Solomon Gashaw Ayele, B. Tesfaye, Gebrehiwot Gebremedihn Tafere, Muzey Gebreyohannes Abrha   +6 more
semanticscholar   +1 more source